| Literature DB >> 34948199 |
Koichi Ogami1, Hiroshi I Suzuki1,2.
Abstract
The genome is pervasively transcribed across various species, yielding numerous non-coding RNAs. As a counterbalance for pervasive transcription, various organisms have a nuclear RNA exosome complex, whose structure is well conserved between yeast and mammalian cells. The RNA exosome not only regulates the processing of stable RNA species, such as rRNAs, tRNAs, small nucleolar RNAs, and small nuclear RNAs, but also plays a central role in RNA surveillance by degrading many unstable RNAs and misprocessed pre-mRNAs. In addition, associated cofactors of RNA exosome direct the exosome to distinct classes of RNA substrates, suggesting divergent and/or multi-layer control of RNA quality in the cell. While the RNA exosome is essential for cell viability and influences various cellular processes, mutations and alterations in the RNA exosome components are linked to the collection of rare diseases and various diseases including cancer, respectively. The present review summarizes the relationships between pervasive transcription and RNA exosome, including evolutionary crosstalk, mechanisms of RNA exosome-mediated RNA surveillance, and physiopathological effects of perturbation of RNA exosome.Entities:
Keywords: RNA exosome; cofactor; disease; evolution; genome; pervasive transcription
Mesh:
Substances:
Year: 2021 PMID: 34948199 PMCID: PMC8707817 DOI: 10.3390/ijms222413401
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of RNA exosome and pathways leading RNA substrates to the catalytic subunits. (a) The core RNA exosome (EXO9) is composed of nine subunits and is further divided into two structures, “cap” S1/KH ring and “barrel” PH-ring. Two catalytic subunits EXOSC10 and DIS3 are placed near the cap and at the bottom of barrel, respectively. (b) Three distinct pathways identified so far, which lead RNA 3′ end to either of the two catalytic subunits. Threading pathway: RNA is threaded into the central channel of the core exosome and brought to the active site of DIS3; Traversing pathway to Rrp6: RNA traverses the cap structure, reaching the active site of Rrp6; and Direct access to Rrp44: RNA directly accesses Rrp44 without entering the central channel.
Figure 2The human adaptor complexes guiding specific RNA substrates for exosome-mediated RNA degradation or processing. Note that the RNA helicase MTR4 is commonly present in all the adaptor complexes.
Figure 3Dependencies on exosome-related genes in cancer cell lines and the alteration frequencies in human cancers. (a) A chart showing the percentage out of 1054 cancer cell lines, in which the dependency for a given CRISPR target gene is identified in the Cancer Dependency Map (DepMap). A cell line with a probability of dependency greater than 0.5 was considered as dependent [101]. Note that the data for a NEXT component ZCCHC8 is unavailable in DepMap. (b–d) Heatmaps showing the percentage of TCGA cases, in which (b) amplifications, (c) deletions or (d) mutations in given genes were evident. DepMap and cBioPortal were accessed in November of 2021. LAML, Acute Myeloid Leukemia; ACC, Adrenocortical Carcinoma; BLCA, Bladder Urothelial Carcinoma; LGG, Brain Lower Grade Glioma; BRCA, Breast Invasive Carcinoma; CESC, Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma; CHOL, Cholangiocarcinoma; COADREAD, Colorectal Adenocarcinoma; DLBC, Diffuse Large B-Cell Lymphoma; ESCA, Esophageal Carcinoma; GBM, Glioblastoma Multiforme; HNSC, Head and Neck Squamous Cell Carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney Renal Clear Cell Carcinoma; KIRP, Kidney Renal Papillary Cell Carcinoma; LIHC, Liver Hepatocellular Carcinoma; LUAD, Lung Adenocarcinoma; LUSC, Lung Squamous Cell Carcinoma; MESO, Mesothelioma; OV, Ovarian Serous Cystadenocarcinoma; PAAD, Pancreatic Adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; PRAD, Prostate Adenocarcinoma; SARC, Sarcoma; SKCM, Skin Cutaneous Melanoma; STAD, Stomach Adenocarcinoma; TGCT, Testicular Germ Cell Tumors; THYM, Thymoma; THCA, Thyroid Carcinoma; UCS, Uterine Carcinosarcoma; UCEC, Uterine Corpus Endometrial Carcinoma; and UVM, Uveal Melanoma.